Physician profile
Aneel Kumar Bole
NPI 1275822264
$18,752.84
in general payments reported to CMS, 2019-2025
30 companies · $1,568 in 2025
The $1,568 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,930 · 2020: $16.41 · 2021: $1,536 · 2022: $1,786 · 2023: $3,886 · 2024: $4,030 · 2025: $1,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,653 · Travel and Lodging: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,652.83 |
| Travel and Lodging | $831.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $4,742.34 | 2022-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Edwards Lifesciences Corporation | $3,345.00 | 2019-2023 | |
| Medtronic Vascular, INC. | $1,468.94 | 2019 | |
| Baylis Medical Company INC | $1,374.83 | 2021 | |
| Medical Device Business Services, INC. | $1,331.10 | 2019 | |
| Boston Scientific Corporation | $1,328.59 | 2021-2025 | Watchman Flx, General - Therapies, Rotapro |
| Medtronic, INC. | $869.53 | 2022-2025 | Corevalve Evolut R, Resolute Onyx, Symplicity G3 |
| W. L. Gore & Associates, INC. | $762.56 | 2023-2025 | Gore Cardioform Septal Occluder |
| Abiomed | $581.02 | 2019-2024 | Impella |
| Stryker Corporation | $500.54 | 2025 | Limflow System, Flowtriever, Flowtriever Catheter, S |
| Amgen INC. | $386.70 | 2022-2025 | Repatha |
| Abbott Laboratories | $314.52 | 2019-2024 | Amplatzer Amulet |
| E.R. Squibb & Sons, L.L.C. | $202.07 | 2022-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $198.02 | 2022-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.66 | 2023-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $174.29 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $165.56 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $156.17 | 2022 | |
| Cardiovascular Systems INC. | $148.73 | 2019-2023 | Diamondback Peripheral |
| Esperion Therapeutics, INC. | $146.01 | 2022-2023 | Nexletol |
| Penumbra, INC. | $119.89 | 2022 | |
| Pfizer INC. | $61.12 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $39.08 | 2021-2022 | |
| Heartflow, INC. | $38.24 | 2025 | |
| Novo Nordisk INC | $34.77 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.46 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.05 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.68 | 2022 | |
| Terumo Medical Corporation | $15.45 | 2025 | Optitorque, Glidewire |
| Regeneron Healthcare Solutions, INC. | $13.92 | 2025 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aneel Bole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.